220 related articles for article (PubMed ID: 35258435)
1. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
3. Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy.
Qin Y; Bollin K; de Macedo MP; Carapeto F; Kim KB; Roszik J; Wani KM; Reuben A; Reddy ST; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Lazar AJ; Hwu P; Patel SP
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203661
[TBL] [Abstract][Full Text] [Related]
4. Determinants of overall survival in patients with metastatic uveal melanoma.
Demkowicz P; Pointdujour-Lim R; Miguez S; Lee Y; Jones BSCL; Barker CA; Bosenberg M; Abramson DH; Shoushtari AN; Kluger H; Francis JH; Sznol M; Bakhoum MF
Cancer; 2023 Oct; 129(20):3275-3286. PubMed ID: 37382208
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
[TBL] [Abstract][Full Text] [Related]
7. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
8. Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.
Botticelli A; Cirillo A; Pomati G; Cortesi E; Rossi E; Schinzari G; Tortora G; Tomao S; Fiscon G; Farina L; Scagnoli S; Pisegna S; Ciurluini F; Chiavassa A; Amirhassankhani S; Ceccarelli F; Conti F; Di Filippo A; Zizzari IG; Napoletano C; Rughetti A; Nuti M; Mezi S; Marchetti P
Cancer Immunol Immunother; 2023 Jul; 72(7):2217-2231. PubMed ID: 36869232
[TBL] [Abstract][Full Text] [Related]
9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
10. Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.
Stålhammar G; Seregard S; Grossniklaus HE
Cancer Med; 2019 Jun; 8(6):2784-2792. PubMed ID: 30993893
[TBL] [Abstract][Full Text] [Related]
11. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma.
Bol KF; Ellebaek E; Hoejberg L; Bagger MM; Larsen MS; Klausen TW; Køhler UH; Schmidt H; Bastholt L; Kiilgaard JF; Donia M; Svane IM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623302
[TBL] [Abstract][Full Text] [Related]
12. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
13. Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Qin Y; Petaccia de Macedo M; Reuben A; Forget MA; Haymaker C; Bernatchez C; Spencer CN; Gopalakrishnan V; Reddy S; Cooper ZA; Fulbright OJ; Ramachandran R; Wahl A; Flores E; Thorsen ST; Tavera RJ; Conrad C; Williams MD; Tetzlaff MT; Wang WL; Gombos DS; Esmaeli B; Amaria RN; Hwu P; Wargo JA; Lazar AJ; Patel SP
Oncoimmunology; 2017; 6(6):e1321187. PubMed ID: 28680759
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives.
Kaštelan S; Antunica AG; Oresković LB; Pelčić G; Kasun E; Hat K
Curr Med Chem; 2020; 27(8):1350-1366. PubMed ID: 31272342
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients.
Grynberg S; Stoff R; Asher N; Shapira-Frommer R; Schachter J; Haisraely O; Lawrence Y; Ben-Betzalel G
Ther Adv Med Oncol; 2022; 14():17588359221131521. PubMed ID: 36339927
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation and prognostic values of immune-escape genes in uveal melanoma.
Basile MS; Mazzon E; Russo A; Mammana S; Longo A; Bonfiglio V; Fallico M; Caltabiano R; Fagone P; Nicoletti F; Avitabile T; Reibaldi M
PLoS One; 2019; 14(1):e0210276. PubMed ID: 30653520
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in uveal melanoma: novel strategies and opportunities for personalized treatment.
Masaoutis C; Kokkali S; Theocharis S
Expert Opin Investig Drugs; 2021 May; 30(5):555-569. PubMed ID: 33650931
[TBL] [Abstract][Full Text] [Related]
18. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Circulating Metabolome of Patients with Cutaneous, Mucosal and Uveal Melanoma Reveals Distinct Metabolic Profiles with Implications for Response to Immunotherapy.
Vilbert M; Koch EC; Rose AAN; Laister RC; Gray D; Sotov V; Penny S; Spreafico A; Pinto DM; Butler MO; Saibil SD
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509369
[TBL] [Abstract][Full Text] [Related]
20. Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
Strobel K; Bode B; Dummer R; Veit-Haibach P; Fischer DR; Imhof L; Goldinger S; Steinert HC; von Schulthess GK
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1774-82. PubMed ID: 19495748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
